ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
30 announcements
Astal Laboratories will hold a board meeting on 13 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The trading window stays closed until 48 hours after the meeting.
Astal Laboratories submitted the Regulation 74(5) certificate from its Registrar for the quarter ended September 30, 2026, confirming the dematerialization activities.
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.
Promoter Aceso Research Labs LLP acquired 25,417 equity shares of Astal Laboratories Ltd via market purchase, increasing their stake from 4.53% to 4.59%.
Astal Laboratories' promoter ACESO Research Labs LLP bought equity shares on BSE under a SEBI PIT disclosure. The open-market purchase signals promoter confidence.
Astal Laboratories has submitted its Annual Report for the financial year 2025-26 and the notice for its 33rd Annual General Meeting scheduled for September 29, 2026.
Astal Laboratories will hold its 33rd Annual General Meeting on September 29, 2026. The company also announced book closure and e-voting dates.
Astal Laboratories Limited appointed Avnesh Jain & Co. as Cost Auditors for the financial year 2026-27.
Astal Laboratories approved its Board Report, appointed Cost Auditors, and scheduled its 33rd Annual General Meeting for September 29, 2026, alongside related administrative matters.
Astal Laboratories Limited has scheduled a board meeting on September 04, 2026, to approve the notice of the 33rd AGM and the Board Report.
Astal Laboratories submitted a statement confirming no deviation in the utilization of previously raised funds for the quarter ended June 30, 2026, as per SEBI regulations.
Astal Laboratories Ltd reported revenue from operations of ₹100.9 Cr and net profit of ₹9.4 Cr for Q1 FY27.
Astal Laboratories Ltd will hold a board meeting on August 14, 2026, to consider and approve the unaudited standalone and consolidated financial results.
Astal Laboratories converted 1,13,300 warrants into equity shares. Additionally, 1,86,700 warrants lapsed and were forfeited by the company during the quarter.
Astal Labs approved a Rs.300 Crore fund raise via private placement of convertible and non‑convertible instruments. The board also cleared a mandate to seek USFDA/EU‑GMP manufacturing unit acquisitions.
Astal Laboratories Limited resubmitted its audited standalone and consolidated financial results for FY2026. The revision addresses a typographical error in the company's earlier regulatory filing.
Astal Laboratories reported nil deviation in the utilization of ₹3.06 Crore raised via a preferential issue. Funds were deployed for capital expenditure and working capital requirements.
Astal Laboratories Ltd reported revenue from operations of ₹134 Cr (+470.2% YoY) and net profit of ₹7.7 Cr (+185.2% YoY) for Q4 FY26.
Astal Laboratories Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The board also re-appointed M/s VRPS & Co. as internal auditors.
Astal Laboratories submitted its Annual Secretarial Compliance Report for FY2026. The auditor reported full regulatory compliance with no adverse observations or penalties recorded.
Astal Laboratories forfeited ₹0.19 Crore after 1,86,700 convertible warrants lapsed without being exercised. The warrants expired on May 26, 2026, after an 18-month conversion period.
Astal Laboratories scheduled a board meeting for May 30, 2026, to approve FY2026 audited financial results. The trading window remains closed until 48 hours post-meeting.
Astal Laboratories allotted 1,13,300 equity shares upon warrant conversion, raising Rs. 0.45 Crore. This conversion by non-promoters increases the company's total paid-up equity capital.
Astal Laboratories appointed M/s. Khedar Ankur & Associates as statutory auditors for its material subsidiary, Sriven Pharmachem. The appointment fills a casual vacancy following previous auditor resignation.
Statutory auditors of Astal Laboratories' material subsidiary resigned effective May 13, 2026, due to pending Peer Review certification. The departure follows updated SEBI regulatory requirements.
Astal Laboratories allotted 14,70,000 equity shares following warrant conversions, raising ₹5.88 Crore. The allotment increases paid-up capital and expands the non-promoter equity base.
Astal Laboratories clarified that recent stock price movements are purely market-driven. The company confirmed no undisclosed material information exists that could influence trading activity.
Astal Laboratories Limited has informed the BSE about its official website address, https://astallabs.com/, in compliance with SEBI Listing Regulations. The website contains all mandatory disclosures required under Regulation 46.